Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia
- Lili Tao†1, 2,
- Qingshu Zeng†3,
- June Li4, 5, 6,
- Miao Xu4, 6,
- Jiajia Wang1, 2,
- Ying Pan1, 2,
- Huiping Wang1, 2,
- Qianshan Tao1, 2,
- Yang Chen3,
- Jun Peng7,
- Ming Hou7,
- Arend Jan Gerard Jansen8, 9,
- Heyu Ni4, 5, 6, 10Email author and
- Zhimin Zhai1, 2Email author
© The Author(s). 2017
Received: 3 January 2017
Accepted: 1 February 2017
Published: 8 February 2017
Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder. Despite considerable investigation, the pathogenesis of ITP remains incompletely understood, and for many patients, effective therapy is still unavailable. Using murine models and in vitro studies of human blood samples, we recently identified a novel Fc-independent platelet clearance pathway, whereby antibody-mediated desialylated platelets can be cleared in the liver via asialoglycoprotein receptors, leading to decreased response to standard first-line therapies targeting Fc-dependent platelet clearance. Here, we evaluated the significance of this finding in 61 ITP patients through correlation of levels of platelet desialylation with the efficacy of first-line therapies. We found that desialylation levels between different responses to treatment groups were statistically significant (p < 0.01). Importantly, correlation analysis indicated response to treatment and platelet desialylation were related (p < 0.01), whereby non-responders had significantly higher levels of platelet desialylation. Interestingly, we also found secondary ITP and certain non-ITP thrombocytopenias also exhibited significant platelet desialylation compared to healthy controls. These findings designate platelet desialylation as an important biomarker in determining response to standard treatment for ITP. Furthermore, we show for the first time platelet desialylation in other non-ITP thrombocytopenias, which may have important clinical implications and deserve further investigation.
KeywordsPlatelet Immune thrombocytopenia Antibody Desialylation Steroid and IVIG therapy
Immune thrombocytopenia (ITP) is a common clinical bleeding disorder characterized by an immune-mediated clearance of autologous platelets, predominantly through autoantibodies targeting platelet surface receptors GPIIbIIIa and/or GPIb-IX and clearance by phagocytic cells in the reticuloendothelial system via Fcγ-receptors [1–4]. Low platelet counts place ITP patients at risk for severe bleeding including fatal intracranial hemorrhage. Most therapies for ITP including first-line corticosteroids and immunoglobulin G (IVIG), and last resort splenectomy, mainly target the Fc-dependent clearance pathway via blocking/attenuating Fc-Fcγ-R interaction or removal of putative site of platelet clearance . However, the pathogenesis and mechanisms of therapies remain poorly understood and around 15–20% of ITP patients are inexplicably refractory to first-line therapies, and around 10% are refractory to splenectomy [5, 6]. In recent years, murine models and large cohort human studies report antibody specificity (i.e., anti-GPIIbIIIa versus anti-GPIb-IX) may play a significant role in dictating response to therapy in ITP [7–9]; whereby presence of anti-GPIb-IX antibodies results in decreased response to corticosteroids and IVIG [7–9]. Most recently, we reported that anti-GPIbα and some anti-GPIIbIIIa antibodies in humans induced platelet desialylation leading to Fc-independent platelet clearance in the liver via hepatic asialoglycoprotein Ashwell-Morell receptors , suggesting antibody-mediated desialylation may be one of the underlying mechanisms behind resistance to standard ITP therapies [8, 9, 11].
Platelet desialylation of different groups [M (P 25, P 75)]
ITP (n = 61)
43 ± 18
16.0 ± 12.5
Efficacy grouping (n = 61)
CR (n = 26)
36 ± 16
16.1 ± 15.3
R (n = 21)
44 ± 19
17.2 ± 10.5
NR (n = 14)
52 ± 17
13.9 ± 9.7
Antibody grouping (n = 33)
Anti-GPIbα (+) (n = 9)
39 ± 14
10.7 ± 5.3
Single anti-GPIIbIIIa (+) (n = 14)
35 ± 16
16.0 ± 14.5
Double negative (n = 10)
41 ± 17
14.9 ± 9.7
CTD (n = 10)
43 ± 20
20.3 ± 20.0
MDS (n = 10)
51 ± 27
29.3 ± 18.4
AA (n = 6)
31 ± 11
28.2 ± 9.6
AML (n = 8)
49 ± 19
19.4 ± 18.6
Healthy control (n = 20)
41 ± 12
197.7 ± 61.7
To test whether the presence of anti-GPIbα antibodies is associated with the platelet desialylation, we detected antibody using MAIPA in the available 33 patient samples collected prior to treatment. We observed a two- to sixfold increased platelet desialylation in patients with anti-GPIbα antibodies (n = 9) compared to that in patients with anti-GPIIbIIIa (n = 14) or without detectable antibodies (n = 10) (Table 1 and Fig. 1B). However, statistical significance was not reached, which is likely due to small sample size. Future larger studies should be useful in determining direct correlation between anti-GPIbα antibody positivity with platelet desialylation.
Interestingly, we also observed significant platelet desialylation in patients with non-ITP thrombocytopenias including connective tissue diseases (CTD), myelodysplastic syndrome (MDS), and aplastic anemia (AA) (p < 0.001) but not acute myeloid leukemia (AML) compared to healthy controls (Table 1 and Fig. 1B). Notably, although RCA-1 and ECL measures different types of deglycosylation, we did not observe significant difference between these two assays, suggesting either of them can be used for the potential diagnosis and prognosis.
In summary, our data demonstrates for the first time that the higher level of platelet desialylation is correlated with non-response to the first-line ITP therapies (likely also splenectomies; Additional file 1: Supplementary Material). These findings not only suggest that platelet desialylation is a useful biomarker in predicting response to treatment in clinical ITP but positions sialidase inhibitors, such as Tamiflu , as a potential novel therapeutic in the treatment of ITP as well as other thrombocytopenias.
Acute myeloid leukemia
Connective tissue disease
Erythrina cristagalli lectin
Intravenous immunoglobulin G
Monoclonal antibody immobilization of platelet antigen assay
Ricinus communis agglutinin I
The authors would like to thank Mr. Thomas McKeown, Miss Xun Fu, and Miss Jade Sullivan for editing the manuscript.
This work was supported by the Canadian Institutes of Health Research (MOP 97918, MOP 119540, MOP 119551); Canadian Blood Services-Canadian Institutes of Health Research partnership fund (CIHR-BUC201403-HN-326400); by the Special Research Funding for the Doctoral Program (NO. 20103420110001), Ministry of Education, People’s Republic of China; and by the Foundation of the Second Affiliated Hospital and the Hematological Research Center, Anhui Medical University, People’s Republic of China. June Li is a recipient of Ph.D. Graduate Fellowship from Canadian Blood Services. Miao Xu is a recipient of the State Scholarship Fund from the China Scholarship Council and Ontario Trillium Scholarship, Canada.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
LT planned and carried out the experiments, analyzed the data, and prepared the manuscript. QZ supervised the clinical studies and analyzed the data. LJ and MX analyzed the data and prepared the manuscript. JW, YP, HW, QT, and YC carried out the experiments and analyzed the data. AJGJ, JP, and MH joined the international collaboration group meetings, analyzed the data and contributed to the preparation of manuscript. HN and ZZ (PIs) supervised the research, analyzed the data, and prepared the manuscript. LT and QZ contributed equally to this work and should be acknowledged as co-first authors. Both Dr. HN and Dr. ZZ should be acknowledged as co-corresponding authors. All authors read and approved the final manuscript.
The contact information for the corresponding authors:
Heyu Ni, M.D.; Ph.D, Professor, Department of Laboratory Medicine and Pathobiology, Department of Medicine, and Department of Physiology, University of Toronto; Scientist of Canadian Blood Services Centre for Innovation; Platform Director for Hematology, Cancer and Immunological Diseases, St. Michael’s Hospital, Room 420, LKSKI - Keenan Research Centre, 209 Victoria Street, Toronto, Ontario, M5B 1W8, CANADA. Tel: 1-416-847-1738; Email: firstname.lastname@example.org
Zhimin Zhai, M.D.; PhD. Professor, Director of Department of Hematology, The Second Affiliated Hospital and the Hematological Research Center, Anhui Medical University, Hefei 230601, China. Tel: 86-138-5514-7434; Email: email@example.com
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
The study has been approved by the Ethic Board of Anhui Medical University (No. 20131038). Patients in this study all signed informed consents to clinical data use at enrolment.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Rodeghiero F, Michel M, Gernsheimer T, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013;121:2596–606.View ArticlePubMedGoogle Scholar
- Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113:6511–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Lazarus AH, Semple JW, Cines DB. Innate and adaptive immunity in immune thrombocytopenia. Semin Hematol. 2013;50 Suppl 1:S68–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Li J, van der Wal DE, Zhu L, et al. Fc-independent phagocytosis: implications for IVIG and other therapies in immune-mediated thrombocytopenia. Cardiovasc Hematol Disord Drug Targets. 2013;13:50–8.View ArticlePubMedGoogle Scholar
- Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults. Br J Haematol. 2002;118:933–44.View ArticlePubMedGoogle Scholar
- Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005;90:72–7.PubMedGoogle Scholar
- Webster ML, Sayeh E, Crow M, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood. 2006;108:943–6.View ArticlePubMedGoogle Scholar
- Zeng Q, Zhu L, Tao L, et al. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbalpha antibodies. Am J Hematol. 2012;87:206–8.View ArticlePubMedGoogle Scholar
- Peng J, Ma SH, Liu J, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014;12:497–504.View ArticlePubMedGoogle Scholar
- Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 2015;6:7737.View ArticlePubMedPubMed CentralGoogle Scholar
- Li J, Callum JL, Lin Y, et al. Severe platelet desialylation in a patient with glycoprotein Ib/IX antibody-mediated immune thrombocytopenia and fatal pulmonary hemorrhage. Haematologica. 2014;99:e61–63.View ArticlePubMedPubMed CentralGoogle Scholar
- Shao L, Wu Y, Zhou H, et al. Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody. Platelets. 2015;26:495–7.View ArticlePubMedGoogle Scholar